Speerstra F, Reekers P, van de Putte L B, Vandenbroucke J P, Rasker J J, de Rooij D J
J Rheumatol. 1983 Dec;10(6):948-53.
By means of a case-control study we investigated the association between HLA phenotypes and the development of proteinuria after aurothioglucose or D-penicillamine treatment in patients with rheumatoid arthritis (RA). HLA-DR3 was markedly increased in 44 treatment cases compared with 66 RA controls (46 versus 18%, p = 0.002). HLA-DR3 positive patients were at greater risk during treatment with D-penicillamine (RR 10.1, p = 0.001) than gold treated cases (RR 1.7, p = 0.365). The associations between HLA-DR3 and nephrotic syndrome (RR = 6.3, p = 0.004) and early onset proteinuria (RR = 5.4, p less than 0.001) were stronger compared with uncomplicated proteinuria (RR = 3.1, p = 0.017) and late-onset proteinuria (RR = 1.6, p = 0.459), respectively. It appears that genetic factors in RA influence the development, the degree and the time of onset of drug induced proteinuria.
通过一项病例对照研究，我们调查了类风湿关节炎（RA）患者在接受金硫葡萄糖或青霉胺治疗后，HLA表型与蛋白尿发生之间的关联。与66例RA对照相比，44例治疗病例中HLA - DR3显著增加（46%对18%，p = 0.002）。与接受金制剂治疗的病例（RR 1.7，p = 0.365）相比，HLA - DR3阳性患者在接受青霉胺治疗期间风险更高（RR 10.1，p = 0.001）。与单纯蛋白尿（RR = 3.1，p = 0.017）和迟发性蛋白尿（RR = 1.6，p = 0.459）相比，HLA - DR3与肾病综合征（RR = 6.3，p = 0.004）和早发性蛋白尿（RR = 5.4，p < 0.001）之间的关联更强。看来RA中的遗传因素会影响药物性蛋白尿的发生、程度和发病时间。
